Allergen desensitization method
The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.
1. A method for epicutaneous desensitization of a subject allergic to peanut, the method comprising:
a) epicutaneously exposing the subject to a peanut allergen and generating an immune reaction in the subject by applying a dose of the peanut allergen, without an adjuvant, onto an intact region of skin of the subject; and
b) repeatedly applying the peanut allergen, without an adjuvant, to an intact region of the skin of the subject, at a dose, frequency or for an application time adapted to sustain the immune reaction, the exposure and sustained reaction leading to desensitization of the subject;
wherein the peanut allergen is applied by a cutaneous occlusive device configured to ensure contact between the allergen and the region of skin, and wherein said dose of peanut allergen is comprised between 0.1 and 1,000 μg/cm 2 of a surface area of the device.
2. The method of claim 1 , further comprising visually evaluating the immune reaction.
3. The method of claim 1 , wherein the dose, frequency, or application time of the peanut allergen is increased as the immune reaction decreases during the repeated applications.
4. The method of claim 1 , wherein the dose, frequency, or application time of the peanut allergen is decreased as the immune reaction increases during the repeated applications.
5. The method of claim 1 , wherein the peanut allergen is in powder form.
6. The method of claim 1 , wherein the immune reaction generated during the generating step is visible to a naked eye.
7. The method of claim 6 , wherein the immune reaction comprises an infiltrated erythematous lesion.
8. The method of claim 6 , wherein the immune reaction has an eczematiform aspect.
9. The method of claim 1 , wherein the device comprises a transparent backing configured to allow the immune reaction to be viewed.
10. The method of claim 9 , wherein the backing comprises a grid configured to aid in an evaluation of the immune reaction.
11. The method of claim 1 , wherein the device is removable.
12. The method of claim 1 , wherein the peanut allergen comprises peanut proteins.